The last 10 years have seen resurgent industry activity in discovery and development of new drugs for the treatment of tuberculosis (TB), a growing widespread and devastating (more than 2 million deaths annually) bacterial infection that is of increasing concern in developing and developed nations alike. This review describes drugs currently being evaluated in the clinic for treatment of uncomplicated and drug resistant pulmonary TB, and updates the literature on 5 new drugs that entered clinical trials in the last 4 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157340607780620626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitochondrial-derived microproteins: from discovery to function.
Trends Genet
December 2024
Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Given the uniqueness of the mitochondria, and the fact that they have their own genome, mitochondrial-derived microproteins (MDPs) are similar to, but different from, nuclear-encoded microproteins. The discovery of an increasing number of microproteins from this organelle and the importance of mitochondria to cellular and organismal health make it a priority to study this novel class of proteins in search of possible therapeutic targets and cures. In this review, we discuss the history of MDP discovery, describe the function of each MDP, and conclude with future goals and techniques to help discover more MDPs.
View Article and Find Full Text PDFCRISPR CLIP: comprehensive reviews on interventional studies using precision recombinant technologies: clinical landmarks, implications, and prospects.
Oxf Open Immunol
November 2024
Faculty of Medicine, University Geomedi, 3, King Solomon Street, Tbilisi 0114, Georgia.
To consolidate clinical trials that utilized the CRISPR technology to synthesise cures for various genetic diseases as a means to provide a window into the progress made so far while paving the way forward for future research and practices. Systematic review (PROSPERO CRD42023479511). Trials from seven databases' (ClinicalTrials.
View Article and Find Full Text PDFAddressing pain in people living with cystic fibrosis: Cystic fibrosis foundation evidence-informed guidelines.
J Cyst Fibros
December 2024
Department of Family and Preventive Medicine, Division of Palliative Medicine, Emory University, Atlanta, GA, USA.
Even as many outcomes for people living with cystic fibrosis (PLwCF) improve, individuals still experience extensive symptom burdens. From birth, many PLwCF experience both pain as a symptom of their CF disease and procedural pain, posing detriments to health, functioning, and quality of life. Despite its prevalence and impact, there is no CF-specific guidance for the assessment and management of pain.
View Article and Find Full Text PDFMetallodrugs: Synthesis, mechanism of action and nanoencapsulation for targeted chemotherapy.
Biochem Pharmacol
January 2025
UCD School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland. Electronic address:
As a multifactorial and heterogeneous disease, cancer has a high mortality rate, and the search for more effective treatments is an enormous challenge. Metal coordination compounds open a range of possibilities that conventional organic and biological molecules can no longer fulfil due to increasing drug resistance. Metallodrugs still have tremendous potential to help overcome drug resistance and find new cures in medicine, considering that at least 25 metallic elements participate in healthy functioning of the human body.
View Article and Find Full Text PDFEnhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Front Immunol
November 2024
Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!